BRAF and thyroid gland papillary carcinoma: BRAF inhibitor demonstrated excellent response in melanoma35 and also yielded promising result in both anaplastic and papillary thyroid cancer harboring BRAF mutation.36,37 In May 2013, our patient was started on vemurafenib 960 mg twice daily.